Is Amarin Corporation PLC GlaxoSmithKline's New Target?

Published: Aug 02, 2012

After the PHASE III results for AMR-101, Amarin shares (AMRN) traded at almost twenty dollars a share amidst the speculation that a major pharmaceutical company would acquire Amarin. When that event failed to occur, the shares dropped in price, briefly touching the high six dollar range. Now, Amarin has received FDA approval for the drug, now known as Vascepa, and many investors are once again pondering the potential suitors for this small pharmaceutical company. Many names have been tossed into the hat, but one that has not received as much talk as I might have suspected is GlaxoSmithKline (GSK).

Back to news